The Sociedad Española de Oncología Médica (SEOM) is a Spanish non-profit scientific society with the goal to improve prevention, diagnosis, treatment and follow up of cancer by using a multidisciplinary approach. In order to do this, SEOM promotes educational activities and research studies, as well as scientific communications aimed at SEOM members, patients and the general public.
Every year SEOM organizes an annual conference to bring together more than 2,800 professionals in the Oncological field to discuss the latest advances in oncology and encourage collaboration, education and scientific dissemination. This year, SEOM will hold their annual conference in a virtual format during 5 days in October, from Monday 19th to Friday 23d.
This time, MEDSIR will have the privilege to present the findings of a subgroup analysis of the MEDSIR-sponsored clinical trial PARSIFAL in Spanish women with advanced breast cancer (ABC).
PARSIFAL –an international, randomized, open-label phase II trial– aims at exploring the optimal endocrine agent, fulvestrant or letrozole, to combine with palbociclib as initial therapy for endocrine-sensitive, ER[+]/HER2[-] ABC. A total of 486 patients were enrolled in 48 hospitals from 7 different countries and of them 255 were recruited in Spanish sites. Global results of the PARSIFAL trial were presented in May at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Dr. Meritxell Bellet Ezquerra, from the Medical Oncology Department of the Vall d’Hebrón University Hospital in Barcelona (Spain), will present this coming Wednesday 21st of October in the plenary session ‘Advanced Breast Cancer’ (‘Mama avanzada’) the results from the Spanish cohort of PARSIFAL. The details of her oral presentation are the following:
Abstract title: Resultados de la cohorte española del estudio PARSIFAL: Ensayo aleatorizado, abierto, de fase II para evaluar palbociclib (p) en combinación con fulvestrant (f) o letrozole (l) como tratamiento de primera línea en pacientes (pts) con cáncer de mama metastásico (cmm), receptores hormonales positivos
(HR+)/HER2-negativo. (In English: Results from the Spanish cohort of the PARSIFAL study: A randomized, open-label, phase II trial to evaluate palbociclib (P) in combination with fulvestrant (F) or letrozole (L) as first-line treatment in patients (pts) with hormonal receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC)).
Abstract number: O-34
Session: Communications session: advanced breast cancer (17:30-19:00, Wednesday 21st Oct 2020)
We hope to see you online in the plenary session and encourage you all to ask all the questions during the Q&A time.
If you have a project for a clinical trial you can't get out of your head, get in touch with us. We can make it happen.